Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer

Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Metastatic Breast Cancer
• Intervention / Treatment: Drug: Gemcitabine; Drug: Paclitaxel; Drug: Bevacizumab

Detailed Description

This study will evaluate the time-to-progression (TTP) in patients with metastatic breast cancer, receiving 1st line therapy with bevacizumab in combination with paclitaxel and gemcitabine.

Secondary objectives will include response rates and overall survival (OS).

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Stanford, California, United States, 94305
      • Stanford University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

INCLUSION CRITERIA

• Previously-untreated metastatic breast cancer. May have had prior chest wall irradiation or palliative radiation to bony sites for control of pain or fracture. These sites of disease, however, will not be considered as sites of measurable disease.
• Use of bisphosphonates will be permitted.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Granulocyte count ≥ 1500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 8.0 g/dL.
• Serum glutamic oxaloacetic transaminase (SGOT) / serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 x the institutional upper limit of normal (ULN) if alkaline phosphatase is ≤ ULN or alkaline phosphatase may be up to 4 x ULN if transaminases are ≤ ULN.
• Total bilirubin within institutional limits of normal.
• Calculated creatinine clearance ≥ 30 mL/min using the formula: Ccr(mL/min) = [(140-age in years) X (wt in kg) X 0.85 (females)]/(72 x serum creatinine in mg/dL)
• ≥ 18 years of age.
• Prior anthracycline treatment in the adjuvant setting or prior chest wall radiation must have left ventricular ejection fraction (LVEF) within the institutional range of normal as assessed by pre-treatment multigated acquisition (MUGA) scan or echocardiogram (ECHO).
• All patients must give signed written informed consent.
• May have received adjuvant therapy as long as therapy complete > 12 months from study entry.
• Females of childbearing potential must have a negative pregnancy test taken ≤ 2 weeks prior to study enrollment, and must consent to the use of effective contraception during the study period and for 6months thereafter.

EXCLUSION CRITERIA

• Receiving hormonal therapy
• Prior treatment for metastatic disease with cytotoxic agents or inhibitors of epidermal growth factor receptor (EGFR)
• Her2NEU-positive breast cancers, by either immunohistochemistry (IHC) score 3+ or fluorescence in situ hybridization (FISH)
• Pregnant or lactating.
• Patients have had active malignancies other than breast cancer in the past 5 years with the exception of in situ carcinoma of the cervix or nonmelanomatous skin cancer.
• Active or unresolved infection.
• Pre-existing peripheral neuropathy > Grade 1.
• Prior history of severe hypersensitivity reaction to paclitaxel, gemcitabine, bevacizumab or drugs formulated with polysorbate 80.
• Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
• Blood pressure of >150/100 mmHg
• Unstable angina
• New York Heart Association (NYHA) Grade II or greater congestive heart failure
• History of myocardial infarction within 6 months
• History of stroke within 6 months
• Clinically-significant peripheral vascular disease
• Evidence of bleeding diathesis or coagulopathy
• Presence of central nervous system or brain metastases
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
• Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0
• Urine protein:creatinine ratio ≥ 1.0 at screening
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
• Serious, non-healing wound, ulcer, or bone fracture
• Inability to comply with study and/or follow-up procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase II 3-drug regimen; Gemcitabine + Paclitaxel + Bevacizumab	Drug: Gemcitabine; Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles; Other Names: Gemzar; Drug: Paclitaxel; Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles; Other Names: Taxol; Drug: Bevacizumab; Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles; Other Names: Avastin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time-to-Progression (TTP)	Time-to-Progression (TTP) was assessed as the time from start of treatment to progression, as observed on radiographic scans and assessed per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria for progressive disease (ie, a 5-mm absolute increase of the sum of the longest diameters of the target lesions in addition to a 20% increase in the sum of the target lesions)	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response Rates	The best overall response was recorded for each participant from randomization until disease progression/recurrence, using any increase from the smallest measurements recorded since randomization as the indicator of Progressive Disease (PD). Overall response was determined on the basis of response at the target and non-target lesions, and the appearance of new lesions, as follows. Target Nontarget New Lesions Overall Response; Complete Complete None Overall Complete Response; Complete Incomplete response/ None Overall Partial Response Stable Disease (SD); Partial Not PD None Overall Partial Response; SD Not PD None Overall Stable Disease; PD Any Yes/No Overall PD; Any PD Yes/No Overall PD; Any Any Yes Overall PD Overall Response Rate (ORR) was assessed as the sum of the Complete Response (CR) rate and the Partial Response (PR) rate.	24 weeks
Overall Survival (OS), Confirmed	Overall Survival (OS) as determined by confirmed date of death. Participants without documentation as either alive or deceased as of 6 years from the start of treatment were considered lost-to-follow-up.	6 years
Overall Survival (OS), All Participants	Overall Survival (OS), based on date of death or last known date alive	6 years

Collaborators and Investigators

• Sponsor: George Albert Fisher
• Collaborators: Eli Lilly and Company; Genentech, Inc.

Publications and helpful links

General Publications

• Guardino A, et al. "Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer." Cancer Res. 2009;69(24_suppl)abs6089.

Study record dates

Study Major Dates

• Study Start: February 1, 2006
• Primary Completion (Actual): September 1, 2010
• Study Completion (Actual): November 1, 2012

Study Registration Dates

• First Submitted: November 22, 2006
• First Submitted That Met QC Criteria: November 22, 2006
• First Posted (Estimate): November 23, 2006

Study Record Updates

• Last Update Posted (Actual): February 20, 2019
• Last Update Submitted That Met QC Criteria: January 30, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Gemcitabine; Paclitaxel; Bevacizumab
• Other Study ID Numbers: IRB-13761; 96052 (Other Identifier: Stanford University alternate IRB Number); BRSMTS0007 (Other Identifier: OnCore study number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO